175 related articles for article (PubMed ID: 27768862)
1. Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.
Ren S; Luo Y; Chen H; Warburton D; Lam HC; Wang LL; Chen P; Henske EP; Shi W
Am J Pathol; 2016 Dec; 186(12):3261-3272. PubMed ID: 27768862
[TBL] [Abstract][Full Text] [Related]
2. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
4. Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2
Jones AT; Yang J; Narov K; Henske EP; Sampson JR; Shen MH
Neoplasia; 2019 Aug; 21(8):731-739. PubMed ID: 31207499
[TBL] [Abstract][Full Text] [Related]
5. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
[TBL] [Abstract][Full Text] [Related]
6. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1.
Zhou J; Brugarolas J; Parada LF
Hum Mol Genet; 2009 Nov; 18(22):4428-41. PubMed ID: 19692352
[TBL] [Abstract][Full Text] [Related]
7. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
Jones AT; Narov K; Yang J; Sampson JR; Shen MH
Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of
Gewin LS; Summers ME; Harral JW; Gaskill CF; Khodo SN; Neelisetty S; Sullivan TM; Hopp K; Reese JJ; Klemm DJ; Kon V; Ess KC; Shi W; Majka SM
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1201-F1210. PubMed ID: 31461347
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
[TBL] [Abstract][Full Text] [Related]
12. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
[TBL] [Abstract][Full Text] [Related]
13. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
16. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
eNeuro; 2015; 2(6):. PubMed ID: 26693177
[TBL] [Abstract][Full Text] [Related]
17. Hyperplasia and fibrosis in mice with conditional loss of the TSC2 tumor suppressor in Müllerian duct mesenchyme-derived myometria.
Kaneko-Tarui T; Commandeur AE; Patterson AL; DeKuiper JL; Petillo D; Styer AK; Teixeira JM
Mol Hum Reprod; 2014 Nov; 20(11):1126-34. PubMed ID: 25189766
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
Henske EP
Pediatr Nephrol; 2005 Jul; 20(7):854-7. PubMed ID: 15856327
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.
Li S; Takeuchi F; Wang JA; Fan Q; Komurasaki T; Billings EM; Pacheco-Rodriguez G; Moss J; Darling TN
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3539-44. PubMed ID: 18292222
[TBL] [Abstract][Full Text] [Related]
20. Establishment of Tsc2‑deficient rat embryonic stem cells.
Ito Y; Kawano H; Kanai F; Nakamura E; Tada N; Takai S; Horie S; Arai H; Kobayashi T; Hino O
Int J Oncol; 2015 May; 46(5):1944-52. PubMed ID: 25738543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
